Literature DB >> 10980177

In vitro and in vivo antibacterial activities of a new injectable carbapenem, S-4661, against gynaecological pathogens.

H Mikamo1, K Izumi, Y X Hua, Y Hayasaki, Y Sato, T Tamaya.   

Abstract

Carbapenems are often used to treat infections in obstetrics and gynaecology because of their activity against anaerobes. S-4661, a new injectable carbapenem antibiotic, has favourable pharmacokinetic properties and is not hydrolysed by dehydropeptidase I. We investigated the in vitro and in vivo antibacterial activities of S-4661 against strains of Streptococcus agalactiae, Escherichia coli, Peptostreptococcus magnus, Bacteroides fragilis and Prevotella bivia, which are major pathogens in the fields of obstetrics and gynaecology. The MIC(50) and MIC(90) of S-4661 for these strains were 0.25 and 1 mg/L, respectively. The in vivo efficacy of S-4661 was evaluated in a rat model of intrauterine infection, namely pyometra caused by E. coli and B. fragilis. The accumulation of neutrophils in the uterus in the S-4661-treated group was less marked and the number of bacteria significantly lower than those in the untreated group. These results suggest that S-4661 may be useful for treating polymicrobial infections in the fields of obstetrics and gynaecology.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10980177     DOI: 10.1093/jac/46.3.471

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  10 in total

1.  In vitro activities of doripenem and comparator agents against 364 anaerobic clinical isolates.

Authors:  Hannah M Wexler; Adrian E Engel; Daniel Glass; Calida Li
Journal:  Antimicrob Agents Chemother       Date:  2005-10       Impact factor: 5.191

Review 2.  In vitro antibacterial activity of doripenem against clinical isolates from French teaching hospitals: proposition of zone diameter breakpoints.

Authors:  C Lascols; P Legrand; A Mérens; R Leclercq; L Armand-Lefevre; H B Drugeon; M D Kitzis; C Muller-Serieys; M E Reverdy; M Roussel-Delvallez; C Moubareck; A Lemire; A Miara; M Gjoklaj; C-J Soussy
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2010-11-19       Impact factor: 3.267

3.  Activities of doripenem (S-4661) against drug-resistant clinical pathogens.

Authors:  Ronald N Jones; Holly K Huynh; Douglas J Biedenbach
Journal:  Antimicrob Agents Chemother       Date:  2004-08       Impact factor: 5.191

Review 4.  Comparative review of the carbapenems.

Authors:  George G Zhanel; Ryan Wiebe; Leanne Dilay; Kristjan Thomson; Ethan Rubinstein; Daryl J Hoban; Ayman M Noreddin; James A Karlowsky
Journal:  Drugs       Date:  2007       Impact factor: 9.546

5.  In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group.

Authors:  David R Snydman; Nilda V Jacobus; Laura A McDermott
Journal:  Antimicrob Agents Chemother       Date:  2008-10-06       Impact factor: 5.191

Review 6.  Doripenem: a review of its use in the treatment of bacterial infections.

Authors:  Susan J Keam
Journal:  Drugs       Date:  2008       Impact factor: 9.546

7.  In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.

Authors:  Chris M Pillar; Mohana K Torres; Nina P Brown; Dineshchandra Shah; Daniel F Sahm
Journal:  Antimicrob Agents Chemother       Date:  2008-09-08       Impact factor: 5.191

8.  Comparative activities of doripenem versus isolates, mutants, and transconjugants of Enterobacteriaceae and Acinetobacter spp. with characterized beta-lactamases.

Authors:  Shazad Mushtaq; Yigong Ge; David M Livermore
Journal:  Antimicrob Agents Chemother       Date:  2004-04       Impact factor: 5.191

9.  Characteristics of doripenem: a new broad-spectrum antibiotic.

Authors:  Francisco Alvarez-Lerma; Santiago Grau; Olivia Ferrández
Journal:  Drug Des Devel Ther       Date:  2009-09-21       Impact factor: 4.162

10.  Doripenem: A new carbapenem antibiotic a review of comparative antimicrobial and bactericidal activities.

Authors:  Fiona Walsh
Journal:  Ther Clin Risk Manag       Date:  2007-10       Impact factor: 2.423

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.